keyword
MENU ▼
Read by QxMD icon Read
search

Her2 positive breast cancer

keyword
https://www.readbyqxmd.com/read/28324265/cardiac-safety-efficacy-and-correlation-of-serial-serum-her2-extracellular-domain-shed-antigen-measurement-with-the-outcome-of-the-combined-trastuzumab-plus-cmf-in-women-with-her2-positive-metastatic-breast-cancer-results-from-the-eortc-10995-phase-ii-study
#1
Konstantinos Tryfonidis, S Marreaud, H Khaled, B De Valk, J Vermorken, M Welnicka-Jaskiewicz, K Aalders, J M S Bartlett, L Biganzoli, J Bogaerts, David Cameron
PURPOSE: Cardiotoxicity is a side effect of trastuzumab. We assessed efficacy and cardiac safety of CMF with trastuzumab (CMF+T) in HER2-positive metastatic breast cancer patients (MBC). METHODS: In this phase II study, centrally confirmed, previously treated HER2-positive MBC patients with measurable disease (per RECIST v 1.0) were enrolled. Initially, patients were randomized between 8 CMF cycles alone or combined with trastuzumab during chemotherapy, followed by 3-weekly trastuzumab maintenance till progression...
March 21, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28316212/-evaluation-and-classification-of-drug-therapy-for-breast-cancer-with-bone-only-metastasis
#2
X Y Meng, S T Song
Skeleton is one of the most common metastatic organs for breast cancer, which has a better prognosis than visceral metastases. Bone-only metastasis was defined"non-measurable" in the RECIST (Response Evaluation Criteria in Solid Tumors) criteria, and was excluded by clinical trials. However, patients with bone-only metastasis are also in need of effective treatment to prolong survival. Endocrine therapy is the most important treatment for bone metastatic patients. Tumor response of bone metastases can be determined objectively by bone-window CT...
March 23, 2017: Zhonghua Zhong Liu za Zhi [Chinese Journal of Oncology]
https://www.readbyqxmd.com/read/28315938/the-relationship-between-breast-cancer-molecular-subtypes-and-mast-cell-populations-in-tumor-microenvironment
#3
Anna Glajcar, Joanna Szpor, Agnieszka Pacek, Katarzyna Ewa Tyrak, Florence Chan, Joanna Streb, Diana Hodorowicz-Zaniewska, Krzysztof Okoń
Mast cells (MCs) are a part of the innate immune system. The MC functions toward cancer are partially based on the release of chymase and tryptase. However, the MC effect on breast cancer is controversial. The aim of our study was to investigate the presence of MCs in breast cancer tumors of different molecular subtypes and their relationships with other pathological prognostic factors. Tryptase- and chymase-positive mast cell densities were evaluated by immunohistochemistry in 108 primary invasive breast cancer tissue samples...
March 18, 2017: Virchows Archiv: An International Journal of Pathology
https://www.readbyqxmd.com/read/28315505/clinicopathological-and-prognostic-value-of-cd24-expression-in-breast-cancer-a-meta-analysis
#4
Gao Liu, Guo-Xing Liu, Yu Fang, Zhen-Yu Cao, Hui-Hui Du, Jie Fu, Ke Qian
BACKGROUND: A number of studies have been conducted to explore the relationship between CD24 expression and the prognosis of breast cancer; however, the results remain inconsistent. Therefore, we performed this meta-analysis to clarify the impact of CD24 expression on clinicopathological features and prognosis of breast cancer. METHODS: A comprehensive literature search for relevant studies was performed, and statistical analysis was conducted using Stata software...
March 3, 2017: International Journal of Biological Markers
https://www.readbyqxmd.com/read/28315060/results-of-a-phase-ib-trial-of-combination-immunotherapy-with-a-cd8-%C3%A2-t-cell-eliciting-vaccine-and-trastuzumab-in-breast-cancer-patients
#5
G Travis Clifton, Jennifer K Litton, Karen Arrington, Sathibalan Ponniah, Nuhad K Ibrahim, Victor Gall, Gheath Alatrash, George E Peoples, Elizabeth A Mittendorf
BACKGROUND: CD8+ T cell-eliciting vaccines are being investigated in breast cancer patients. Preclinical data showed that trastuzumab increases the susceptibility of tumor cells to lysis by vaccine-generated CD8+ T cells, suggesting potential benefit of a combination immunotherapy strategy. The current trial was undertaken to demonstrate the safety of this approach. METHODS: This study was designed as a dose-escalation trial enrolling clinically disease-free, human leukocyte antigen A2+ or A3+ , human epidermal growth factor receptor 2 (HER2)-positive breast cancer patients...
March 17, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28314836/safe-heart-rationale-and-design-of-a-pilot-study-investigating-cardiac-safety-of-her2-targeted-therapy-in-patients-with-her2-positive-breast-cancer-and-reduced-left-ventricular-function
#6
Filipa Lynce, Ana Barac, Ming T Tan, Federico M Asch, Karen L Smith, Chau Dang, Claudine Isaacs, Sandra M Swain
BACKGROUND: Human epidermal growth receptor 2 (HER2) targeted therapies have survival benefit in adjuvant and metastatic HER2 positive breast cancer but are associated with cardiac dysfunction. Current U.S. Food and Drug Administration recommendations limit the use of HER2 targeted agents to patients with normal left ventricular (LV) systolic function. METHODS: The objective of the SAFE-HEaRt study is to evaluate the cardiac safety of HER2 targeted therapy in patients with HER2 positive breast cancer and mildly reduced left ventricular ejection fraction (LVEF) with optimized cardiac therapy...
March 17, 2017: Oncologist
https://www.readbyqxmd.com/read/28314691/prevention-of-everolimus-related-stomatitis-in-women-with-hormone-receptor-positive-her2-negative-metastatic-breast-cancer-using-dexamethasone-mouthwash-swish-a-single-arm-phase-2-trial
#7
Hope S Rugo, Lasika Seneviratne, J Thaddeus Beck, John A Glaspy, Julio A Peguero, Timothy J Pluard, Navneet Dhillon, Leon Christopher Hwang, Chaitali Nangia, Ingrid A Mayer, Timothy F Meiller, Mark S Chambers, Robert W Sweetman, J Randy Sabo, Jennifer K Litton
BACKGROUND: Stomatitis is a class effect associated with the inhibition of mTOR and is associated with everolimus therapy for breast cancer. Topical steroids might reduce stomatitis incidence and severity, and the need for dose reductions and interruptions of everolimus. Anecdotal use of topical steroid oral prophylaxis has been reported in patients with breast cancer. We aimed to assess dexamethasone-based mouthwash for prevention of stomatitis in patients with breast cancer. METHODS: This US-based, multicentre, single-arm, phase 2 prevention study enrolled women aged 18 years and older with postmenopausal status who had histologically or cytologically confirmed metastatic hormone receptor-positive, HER2-negative breast cancer...
March 14, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28301662/brain-metastases-in-newly-diagnosed-breast-cancer-a-population-based-study
#8
Allison M Martin, Daniel N Cagney, Paul J Catalano, Laura E Warren, Jennifer R Bellon, Rinaa S Punglia, Elizabeth B Claus, Eudocia Q Lee, Patrick Y Wen, Daphne A Haas-Kogan, Brian M Alexander, Nancy U Lin, Ayal A Aizer
Importance: Population-based estimates of the incidence and prognosis of brain metastases at diagnosis of breast cancer are lacking. Objective: To characterize the incidence proportions and median survivals of patients with breast cancer and brain metastases at the time of cancer diagnosis. Design, Setting, and Participants: Patients with breast cancer and brain metastases at the time of diagnosis were identified using the Surveillance, Epidemiology, and End Results (SEER) database of the National Cancer Institute...
March 16, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28299888/the-relationship-of-race-oncotype-dx-and-ki67-in-a-population-highly-screened-for-breast-cancer
#9
Amber A Guth, Jennifer Chun Kim, Shira Schwartz, Jennifer Montes, Rebecca Akiko Snyder, Deborah Axelrod, Freya Schnabel
Oncotype DX recurrence score (ODX) can predict risk of invasive breast cancer recurrence and benefit of chemotherapy. Literature is limited on the relationship of ODX and race in women with hormone receptor positive and node negative/positive disease. Our study examines the relationship between race and clinical characteristics within a population of highly screened women with newly diagnosed breast cancer. The institutional Breast Cancer Database was queried for patients with newly diagnosed breast cancer between January2010 and March2015...
March 2017: Breast Journal
https://www.readbyqxmd.com/read/28298546/64cu-mm-302-positron-emission-tomography-quantifies-variability-of-enhanced-permeability-and-retention-of-nanoparticles-in-relation-to-treatment-response-in-patients-with-metastatic-breast-cancer
#10
Helen Lee, Anthony F Shields, Barry A Siegel, Kathy D Miller, Ian Krop, Cynthia X Ma, Patricia M LoRusso, Pamela N Munster, Karen Campbell, Daniel F Gaddy, Shannon C Leonard, Elena Geretti, Stephanie J Blocker, Dmitri B Kirpotin, Victor Moyo, Thomas J Wickham, Bart S Hendriks
PURPOSE: Therapeutic nanoparticles are designed to deliver their drug payloads through enhanced permeability and retention (EPR) in solid tumors. The extent of EPR and its variability in human tumors is highly debated and has been proposed as an explanation for variable responses to therapeutic nanoparticles in clinical studies. EXPERIMENTAL DESIGN: We assessed the EPR effect in patients using a 64Cu-labeled nanoparticle, 64Cu-MM-302 (64Cu-labeled HER2-targeted PEGylated liposomal doxorubicin), and imaging by Positron Emission Tomography/Computed Tomography (PET/CT)...
March 15, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28294317/the-spectrum-of-brca-mutations-and-characteristics-of-brca-associated-breast-cancers-in-china-screening-of-2991-patients-and-1043-controls-by-next-generation-sequencing
#11
Guan-Tian Lang, Jin-Xiu Shi, Xin Hu, Chen-Hui Zhang, Ling Shan, Chuan-Gui Song, Zhi-Gang Zhuang, A-Yong Cao, Hong Ling, Ke-Da Yu, Li Shan, Meng-Hong Sun, Xiao-Yan Zhou, Wei Huang, Zhi-Ming Shao
To characterize the prevalence of BRCA mutations and characteristics of BRCA carriers in China and to update the clinical recommendations for BRCA testing, we conducted a wide screen for BRCA mutations using next-generation sequencing (NGS). A total of 4,034 Chinese subjects were screened for germline BRCA1/2 mutations, including 2,991 breast cancer patients and 1,043 healthy individuals from the community enrolled as controls. We developed an NGS-based approach to perform BRCA1/2 screening. BRCA mutations were identified in 9...
March 14, 2017: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/28293912/breast-cancer-subtype-distribution-is-different-in-normal-weight-overweight-and-obese-women
#12
Victoria Gershuni, Yun R Li, Austin D Williams, Alycia So, Laura Steel, Elena Carrigan, Julia Tchou
PURPOSE: Obesity is associated with tumor promoting pathways related to insulin resistance and chronic low-grade inflammation which have been linked to various disease states, including cancer. Many studies have focused on the relationship between obesity and increased estrogen production, which contributes to the pathogenesis of estrogen receptor-positive breast cancers. The link between obesity and other breast cancer subtypes, such as triple-negative breast cancer (TNBC) and Her2/neu+ (Her2+) breast cancer, is less clear...
March 14, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28292559/pathological-characterisation-of-male-breast-cancer-results-of-the-eortc-10085-tbcrc-big-nabcg-international-male-breast-cancer-program
#13
Marijn A Vermeulen, Leen Slaets, Fatima Cardoso, Sharon H Giordano, Konstantinos Tryfonidis, Paul J van Diest, Nizet H Dijkstra, Carolien P Schröder, Christi J van Asperen, Barbro Linderholm, Kim Benstead, Renee Foekens, John W M Martens, John M S Bartlett, Carolien H M van Deurzen
AIM: Several prognostic histological features have been established in female breast cancer (BC), but it is unknown whether these can be extrapolated to male BC patients. The aim of this study was to evaluate the prognostic value of several histological features in a large series of male BC. METHODS: Central pathology review was performed for 1483 male BCs collected through part 1 of the European Organisation for Research and Treatment of Cancer (EORTC) International Male BC Program...
March 11, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28291814/are-life-saving-anticancer-drugs-reaching-all-patients-patterns-and-discrepancies-of-trastuzumab-use-in-the-european-union-and-the-usa
#14
Felipe Ades, Christelle Senterre, Dimitrios Zardavas, Evandro de Azambuja, Razvan Popescu, Martine Piccart
BACKGROUND: The development of trastuzumab is considered to be one of the greatest improvements in breast cancer treatment in recent years. This study aims to evaluate changes in the uptake of trastuzumab over the last 12 years and to determine whether its use is proportional to patient needs in the European Union and the USA. METHODS: Using national registry data, the number of new cases of HER2-positive breast cancer patients per year was estimated. The number of likely trastuzumab treatments per year was estimated using trastuzumab procurement data for each country...
2017: PloS One
https://www.readbyqxmd.com/read/28291775/comment-on-nomogram-to-predict-pathologic-complete-response-in-her2-positive-breast-cancer-treated-with-neoadjuvant-systemic-therapy
#15
Kadri Altundag
No abstract text is available yet for this article.
March 14, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28291772/reply-to-comment-on-nomogram-to-predict-pathologic-complete-response-in-her2-positive-breast-cancer-treated-with-neoadjuvant-systemic-therapy
#16
Takeo Fujii, Naoto T Ueno
No abstract text is available yet for this article.
March 14, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28289045/efficacy-and-safety-of-lapatinib-and-trastuzumab-for-her2-positive-breast-cancer-a-systematic-review-and-meta-analysis-of-randomised-controlled-trials
#17
Zhi-Qiao Xu, Yan Zhang, Ning Li, Pei-Jie Liu, Ling Gao, Xin Gao, Xiao-Jing Tie
OBJECTIVES: The anti-HER2 monoclonal antibody trastuzumab and the tyrosine kinase inhibitor lapatinib have complementary mechanisms of action and synergistic antitumour actively in models of HER2-positive breast cancer. However, the efficacy of trastuzumab in combination with lapatinib remains controversial. Therefore, we conducted this meta-analysis to compare combination treatment with lapatinib and trastuzumab to trastuzumab or lapatinib alone in the treatment of HER2-positive breast cancer...
March 13, 2017: BMJ Open
https://www.readbyqxmd.com/read/28288388/increased-life-expectancy-as-a-result-of-non-hormonal-targeted-therapies-for-her2-or-hormone-receptor-positive-metastatic-breast-cancer-a-systematic-review-and-meta-analysis
#18
REVIEW
Rositsa G Koleva-Kolarova, Monika P Oktora, Annelies L Robijn, Marcel J W Greuter, Anna K L Reyners, Erik Buskens, Geertruida H de Bock
This article aimed to assess the clinical effectiveness of non-hormonal targeted therapies (TTs) in terms of increase of median progression-free survival (PFS) and overall survival (OS) in receptor-positive metastatic breast cancer (MBC) patients by performing a systematic review and meta-analysis. We systematically searched relevant randomized controlled trials and extracted data about number of patients on targeted and comparator therapy, receptor status, line of treatment, median PFS and OS, p values, hazard ratios (HRs) and 95% confidence intervals (CI)...
February 20, 2017: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/28286614/is-there-any-concordance-between-of-ihc-with-fish-in-her2-positive-breast-cancer-patients
#19
Mehrdad Payandeh, Masoud Sadeghi, Edris Sadeghi, Alireza Janbakhsh
Background: In developed or developing countries, the most common cancer in women is breast cancer with a pick in 40-50 years in Asia. Herein, we compared the association between IHC with FISH in HER2-positive breast cancer patients and affection of trastuzumab on disease free survival and overall survival (OS). Subjects and Methods: Immunohistochemical (IHC) analysis of hormone receptors and HER2 was performed in 133 patients with breast cancer between 2003 and 2014. Patients were selected for Herceptin adjuvant treatment, according to IHC 3+ or FISH+...
January 1, 2017: International Journal of Hematology-oncology and Stem Cell Research
https://www.readbyqxmd.com/read/28285403/her2-testing-in-gastric-cancer-results-of-a-german-expert-meeting
#20
REVIEW
Florian Lordick, Salah-Eddin Al-Batran, Manfred Dietel, Timo Gaiser, Ralf-Dieter Hofheinz, Thomas Kirchner, Hans H Kreipe, Sylvie Lorenzen, Markus Möhler, Alexander Quaas, Christoph Röcken, Josef Rüschoff, Andrea Tannapfel, Peter Thuss-Patience, Gustavo Baretton
Valid HER2 testing is essential for optimal therapy of patients with HER2-positive gastric cancer and the correct use of first-line chemotherapy. While testing for HER2 status in breast cancer is routinely performed, this is not the case for HER2 testing in gastric cancer and it is usually only performed on clinician request. An interdisciplinary German expert group (pathologists and clinicians) took the challenges of HER2 testing in gastric cancer as an opportunity to address essential aspects and questions for the practical use of HER2 testing in this indication...
March 11, 2017: Journal of Cancer Research and Clinical Oncology
keyword
keyword
59406
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"